Sanofi slashes list price of Lantu s by 78%
®
its most prescribed insulin in the United States, and caps its cost at $35 for all insured patients
Paris, March 16, 2023.
Sanofi announces that it will reduce the US list price of Lantus (insulin glargine injection) 100 units/ml, Sanofi’s most prescribed insulin in the United States, by 78%. The company will also set a $35 cap on the remainder to be paid by Lantus for all patients who have health insurance. This decision confirms Sanofi’s long-standing commitment to ensuring affordable access to medicines for all patients.
These measures, which will come into effect on January 1, 2024, will be in addition to the decisions already taken in June 2022 to reduce the cost of diabetes drugs: the launch of a biosimilar of Lantus at a price reduced by 60% compared to its list price and the capping of the remaining insulin charge at $35 for all people without insurance. With these decisions, all of Sanofi’s access programs ensure that no patient will pay more than $35 for a monthly supply of Lantus. Finally, Sanofi will also reduce the list price of its short-acting insulin Apidra (insulin glulisine injection) 100 units/ml by 70%.
Olivier Bogillot
Director General Medicine United States, Sanofi
“Sanofi believes that no one should have difficulty paying for their insulin and we are proud of the actions we have taken over many years to ensure affordable access to medicines for millions of patients. We launched the unbranded Lantus biosimilar at a price 60% below its list price in June 2022 but, despite this pioneering low price approach, the healthcare system has not been able to take advantage of it by because of its inherent structural challenges. We are pleased to see others join our efforts to help patients, as we now accelerate the transformation of the US insulin market by reducing the list price of our leading insulin. Significant system changes are still needed. Our decision to reduce the list price of our leading insulin must be combined with broader system-wide change to enable patients to save money at the pharmacy. »
Sanofi Access Programs
Sanofi will continue to offer different programs to ensure access and affordability for patients, depending on their health insurance status. Our range of innovative programs includes:
-
100% of insured persons
are eligible for assistance programs to pay the balance payable by Sanofi, regardless of their income or their insurance plan. In 2022, these programs allowed the majority of participating patients to limit their spending to $15 or less for their diabetes medications, for a 30-day supply. -
100% of uninsured people
are eligible for the access program
insulins
Val
you
– regardless of their income level – which allows them to buy one or more Sanofi insulins at 35 dollars for a 30-day supply. The Soliqua (insulin glargine and lixisenatide) injection 100 units/ml and 33 mcg/ml reimbursement offer also allows uninsured individuals to pay as little as $99 per box of pens, for a maximum of two boxes of pens for a 30 day supply.
We also provide free medicines to qualified low and middle income patients under the program
Sanofi Patient Connection
. Some people facing unexpected financial hardship may be eligible for a one-time, immediate one-month supply of their Sanofi medicine while their application is processed.
From 2023, insulins from Sanofi and Soliqua are included in the
Inflation Reduction Act
when covered by the Medicare formulary, saving money on insulin, capping the monthly cost at $35 for seniors on Medicare Part D. This ensures predictable and stable co-payment , whatever the phase, including the “donut hole” (hole of the bagel).Before the entry into force of the
Inflation Reduction Act
Sanofi voluntarily participated in the
Senior Savings Model
of the
Centers for Medicare and Medicaid Services
(CMS), which allowed patients enrolled in participating Part D plans to pay a co-payment of $35 or less for each 30-day prescription of a Sanofi insulin throughout the year.
Every patient has a unique situation, and Sanofi has live support specialists who can be reached at (855) 984-6302 to answer each patient’s questions and help them with their individual situation to find the best resources and the best programs to help reduce out-of-pocket costs.
To learn more about Sanofi’s transparent approach to pricing, see our
2023 Pricing Principles Report
.
About Sanofi
We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Evan Berland
| +1 215 432 0234 | [email protected]
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor Relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| + 1 908 612 7239 | [email protected]
Tarik Elgoutni |
+ 1 617 710 3587 | tarik.e [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Forward-looking statements
This press release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates regarding the marketing and other potential of this product, or regarding anticipated future revenues for this product. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate”, “plan” or “hope”, as well as other similar terms. Although Sanofi’s management believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond Sanofi’s control, which could mean that the actual results and events realized differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include, but are not limited to, unexpected regulatory actions and setbacks, or generally state regulations, which may affect the availability or commercial potential of this product, the fact that this product may not be commercially successful, the uncertainties inherent in the research and development, future clinical data and analysis of existing clinical data relating to this product, including post-marketing, unexpected safety, quality or production problems, competition in general, risks associated with intellectual property, any future litigation relating thereto and the outcome of such litigation, the instability of economic and market conditions, the impact that COVID-19 will have on Sanofi, its customers, suppliers and partners and their financial condition, as well as on its employees and the global economy. These risks and uncertainties also include those discussed or identified in Sanofi’s public filings with the AMF and the SEC, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of the Registration Document. universal registration 2022 of Sanofi, which has been filed with the AMF as well as in the sections “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” of the 2021 annual report on Form 20-F of Sanofi, which has been filed with the SEC. Sanofi makes no commitment to update forward-looking information and statements subject to applicable regulations, in particular articles 223-1 et seq. of the general regulations of the Autorité des marchés financiers.
Attachment